The Intravascular Cooling in the Treatment of Stroke 2/3 Trial (ICTuS2/3)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this trial is to determine whether the combination of thrombolysis and hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke.
| Condition | Intervention | Phase |
|---|---|---|
|
Stroke, Acute |
Device: hypothermia Other: Group1: IV t-PA and normothermia |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke |
- The primary outcome is the proportion of patients achieving a favorable outcome defined as Modified Rankin Scale score of 0 or 1, assessed 90 days after treatment. [ Time Frame: 90 days ] [ Designated as safety issue: No ]
- The NIH Stroke Scale measure of neurologic deficit; the Barthel Index measure of activities of daily living; the Modified Rankin Scale measure of the degree of disability or dependence in daily activities [ Time Frame: 90 days ] [ Designated as safety issue: No ]
- 90 day mortality [ Time Frame: 90 days ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 400 |
| Study Start Date: | June 2010 |
| Estimated Study Completion Date: | April 2017 |
| Estimated Primary Completion Date: | November 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Group1: IV t-PA and normothermia
IV tpa and normothermia
|
Other: Group1: IV t-PA and normothermia
Group 1 will t-PA as standard of care and normothermia
|
|
Active Comparator: Group 2 : IV t-PA and hypothermia
IV tpa and hypothermia
|
Device: hypothermia
Hypothermia is induced using the Celsius Control™ System
Other Name: cooling
|
Detailed Description:
A stroke is usually caused by a blockage in one of the arteries that carries blood to the brain. Research has shown that tissue plasminogen activator (tPA)—a naturally occurring protein that opens blocked arteries by dissolving blood clots — activates the body's ability to dissolve recently formed blood clots and reduces or prevents the brain damage caused by a stroke.
The Food and Drug Administration (FDA) has approved the use of tPA for people having a stroke when taken within 3 hours of stroke onset.
Researchers believe that a lower body temperature (hypothermia) may be beneficial while a stroke is happening because hypothermia may prevent further brain injury, or may make the stroke less damaging.
Patients will receive a standard stroke evaluation, which includes blood tests, a computed tomography (CT) scan, complete physical and neurological examinations, and an electrocardiogram (EKG) to determine eligibility for the study.
There are two study groups - tPA alone or tPA with cooling (hypothermia). Participants will be randomly assigned to one of the two study groups. Length of participation (including observation after the patient leaves the hospital) is 90 days.
This study is part of the Specialized Program of Translational Research in Acute Stroke (SPOTRIAS), which allows researchers to enhance and initiate translational research that ultimately will benefit stroke patients by treating more patients in less than 2 hours, and finding ways to treat additional patients later.
Eligibility| Ages Eligible for Study: | 22 Years to 82 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 22 to 82 years old inclusive
- Patient receiving IV rt-PA using standard guidelines (Appendix II) Page 23
- NIHSS score ≥ 7 and ≤ 20 (right hemisphere) or ≥ 7 and ≤ 24 (left hemisphere) at the time of randomization
- Pre-stroke mRS 0-1
- Able to begin endovascular phase of hypothermia within 2 hours of tPA completion
- Written Informed Consent, signed and dated by the patient (or patient's authorized representative)
Exclusion Criteria:
- Etiology other than ischemic stroke
- Item 1a on NIHSS > 1 at the time of randomization
- Clinical symptoms consistent with brainstem or cerebellar stroke
- Classic lacunar syndrome with imaging confirmation of small deep ischemia, but randomization will not be delayed for neuroimaging other than initial scan to exclude hemorrhage
- Known contraindications to hypothermia, such as known hematologic dyscrasias that affect thrombosis (cryoglobulinemia, Sickle cell disease, serum cold agglutinins), or vasospastic disorders such as Raynaud's or thromboangiitis obliterans
- Known co-morbid conditions that are likely to complicate therapy in the opinion of the investigator, e.g., i. Heart failure (NYHA class III and IV)* ii. Uncompensated arrhythmia iii. Severe Liver disease iv. History of pelvic or abdominal mass likely to compress inferior vena cava v. IVC filters vi. HIV positive vii. Clinically active hypo or hyperthyroidism viii. Renal insufficiency likely to impair meperidine clearance ix. Chronic ethanol abuse
- Pregnancy (All women of child-bearing potential must have a negative pregnancy test, urine or blood, prior to therapy.)
- Medical conditions likely to interfere with patient assessment.
- Known allergy to meperidine or buspirone
- Currently taking or used within previous 14 days MAO-I class of medication.
- Life expectancy < 6 months
- Not likely to be available for long-term follow-up
- Use, or planned use, of intra-arterial thrombolysis, mechanical clot removal, or other experimental or approved acute therapy for this stroke event
- Chest radiograph or clinical presentation suggestive of pneumonia at baseline.
- Temperature upon admission greater than or equal to 38°C
Contacts and Locations| Contact: Patrick D. Lyden, MD | 310-423-5166 | patrick.lyden@cshs.org |
| Contact: Teresa Rzesiewicz, RN, MSN, PHN | 858-657-7185 | trzesiewicz@ucsd.edu |
| United States, California | |
| Cedars-Sinai Medical Center | Recruiting |
| Los Angeles, California, United States, 90048 | |
| Principal Investigator: Patrick D. Lyden, MD | |
| University of California | Recruiting |
| San Diego, California, United States, 92093 | |
| Principal Investigator: Thomas M. Hemmen, MD, PhD | |
| Scripps Mercy Medical Center | Recruiting |
| San Diego, California, United States, 92103 | |
| Principal Investigator: Gilda Tafreshi, MD | |
| United States, Florida | |
| Intercoastal Medical Group | Recruiting |
| Sarasota, Florida, United States, 34232 | |
| Principal Investigator: Mauricia Concha, MD | |
| United States, Minnesota | |
| North Memorial Medical Center | Recruiting |
| Robbinsdale, Minnesota, United States, 55422 | |
| Principal Investigator: Irfan Altafullah, MD | |
| United States, Texas | |
| University of Texas Health Science Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: James C. Grotta, MD | |
| Principal Investigator: | Patrick D. Lyden, MD | Cedars-Sinai Medical Center |
| Study Director: | Thomas M. Hemmen, MD, PhD | University of California, San Diego |
| Study Director: | James C. Grotta, MD | The University of Texas Health Science Center, Houston |
More Information
Publications:
| Responsible Party: | Patrick Lyden, Principal Investigator, Cedars-Sinai Medical Center |
| ClinicalTrials.gov Identifier: | NCT01123161 History of Changes |
| Other Study ID Numbers: | ICTuS2/3, P50NS044148 |
| Study First Received: | April 27, 2010 |
| Last Updated: | May 8, 2013 |
| Health Authority: | United States: Institutional Review Board United States: Food and Drug Administration |
Keywords provided by University of California, San Diego:
|
Hypothermia Molecular Mechanisms of Pharmacological Action Cerebral Infarction Hematologic Agents Stroke Nervous System Diseases Vascular Diseases Tissue Plasminogen Activator Central Nervous System Diseases Fibrinolytic Agents Cardiovascular Agents Body Temperature Changes Brain Diseases |
Cerebrovascular Disorders Pharmacologic Actions Signs and Symptoms Fibrin Modulating Agents Therapeutic Uses Brain Ischemia Cardiovascular Diseases Brain Infarction Plasminogen cooling tPA thrombolysis |
Additional relevant MeSH terms:
|
Hypothermia Stroke Cerebral Infarction Body Temperature Changes Signs and Symptoms Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases |
Brain Infarction Brain Ischemia Cardiovascular Agents Tissue Plasminogen Activator Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Pharmacologic Actions Hematologic Agents |
ClinicalTrials.gov processed this record on May 23, 2013